New research suggests that individuals who discontinue new slimming jabs like semaglutide or tirzepatide can put back on shed pounds far faster than those who end conventional lifestyle programs.
Published data in a leading medical journal points out that while obese individuals often shed a large proportion of their body weight while on the medication, the mass is regained at an average rate of 0.8 kg per month once they quit.
"Users purchasing such treatments need to be aware of the risk of fast rebound weight gain when the treatment ends," stated lead investigator Dr. Susan Jebb.
This pace of recovery suggests a return to original weight in about one and a half years.
Analyzing Treatments
The study, which examined dozens of trials involving thousands of participants, contrasted the outcomes of GLP-1 agonists with conventional dieting.
Researchers point out that individuals who shed pounds through diet and exercise typically have a less rapid creep back—around 0.1 kg a month—post-intervention.
The Reason for the Rapid Regain
Experts suggest the mode of action of the injections accounts for the amplified weight return.
The injections copy a body's own chemical called GLP-1, which helps regulate appetite.
"Long-term administration of GLP-1 levels far above than normal may cause the body to produce less of its endogenous GLP-1, and may also lessen sensitivity to its effects," explained Dr. Adam Collins, a nutrition expert.
"Stopping of this hormone supplement leads to appetite is uncontrolled, making excessive eating much more probable."
A Lifelong Condition?
Health authorities recommend the jabs for individuals with weight-linked health risks, alongside recommended diet and exercise modifications.
Professionals contend that, due to the significant potential of weight regain, the therapy should be considered long-term.
This opinion is supported by drug manufacturers, who note that the results "underscore the persistent nature of excess weight," akin to managing conditions like high blood pressure.
Patient Testimonies
Users who have stopped the medication report a powerful resurgence of hunger.
"It was like something that goes on and I was suddenly ravenous," recalled a patient.
This challenge is compounded if users have not adopted sustainable lifestyle or habit modifications during treatment.
Widespread Interest
Survey data indicate that millions of people in the UK have used these injections in the last 12 months, with demand remaining high.
- Use is more common among females compared to men.
- The middle-aged age group shows the greatest level of interest.
- A large proportion access the medications through private prescriptions rather than the NHS.
Finally, researchers emphasize that while GLP-1 drugs are potent agents for shedding pounds, they are not a standalone cure and maintained weight loss relies on combined lifestyle changes.